Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioCardia ( (BCDA) ) has issued an announcement.
On June 30, 2025, BioCardia, Inc. completed a private placement agreement with institutional buyers and company insiders, raising approximately $570,000. The funds will be used for general corporate purposes, and the company plans to register the shares for resale with the SEC by July 10, 2025.
The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
BioCardia’s overall stock score is influenced predominantly by its financial instability, characterized by ongoing losses and high leverage. While recent corporate events and clinical advancements provide some positive outlook, they are outweighed by the financial challenges and weak market valuation.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc. operates in the biotechnology industry, focusing on the development of cellular and biotherapeutic technologies for the treatment of cardiovascular diseases. The company’s primary product is the CardiAMP Cell Therapy System, which targets heart failure and other cardiac conditions.
Average Trading Volume: 69,860
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.36M
Learn more about BCDA stock on TipRanks’ Stock Analysis page.